利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.016 秒)

    CHEMICAL COMPOUNDS
    1.
    发明公开
    CHEMICAL COMPOUNDS 审中-公开

    公开(公告)号：EP3904365A1

    公开(公告)日：2021-11-03

    申请号：EP21180706.0

    申请日：2004-07-20

    申请人： NuCana plc

    发明人： McGUIGAN, Christopher

    IPC分类号： C07H19/10 ,  A61K31/7068 ,  A61K31/7072 ,  A61P35/00 ,  A61P43/00

    摘要： Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety. The α-amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.

    CRYSTALLINE FORM OF GEMCITABINE-(S)-PHOSPHATE DIASTEREOISOMER
    2.
    发明公开
    CRYSTALLINE FORM OF GEMCITABINE-(S)-PHOSPHATE DIASTEREOISOMER 审中-公开

    公开(公告)号：EP3725794A1

    公开(公告)日：2020-10-21

    申请号：EP20172701.3

    申请日：2015-09-29

    申请人： NuCana plc

    发明人： GRIFFITH, Hugh

    IPC分类号： C07H19/10

    摘要： This application relates to a method of separating the phosphate diastereoisomers of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate (NUC-1031) using crystallisation. In particular, crystallisation from isopropyl alcohol provides gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate in high diastereoisomerically pure form. This application also relates to a crystalline form of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate.

    CANCER TREATMENTS
    5.
    发明授权
    CANCER TREATMENTS 有权
    癌症治疗

    公开(公告)号：EP3197456B1

    公开(公告)日：2018-04-04

    申请号：EP15726258.5

    申请日：2015-05-14

    申请人： NuCana plc

    发明人： GRIFFITH, Hugh ,  MCGUIGAN, Chris ,  PEPPER, Chris

    IPC分类号： A61K31/513 ,  A61P35/00

    CPC分类号： A61K31/7068 ,  A61K31/513 ,  A61P35/00

    摘要： Disclosed is NUC-1031 (gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate), a ProTide derivative of gemcitabine, for use in targeting cancer stem cells. This targeting of cancer stem cells may be employed in the prevention or treatment of cancer. NUC-1031 may be used in treatment of relapsed or refractory cancer in a human patient. Without wishing to be bound by any hypothesis, it is believed that the ability of NUC-1031 to target cancer stem cells contributes to its utility in the treatment of relapsed or refractory cancers.